BIOCARTIS GROUP NV 144A-Reg S Aktie

0,2595 EUR -0,0510 EUR -16,43 %

25.09.2023

FSE

0,2900 EUR ±0,0000 EUR ±0,00 %

26.09.2023

BTE

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Bei einem anderen Broker handeln Smartphone

Marktkap.27,24 Mio. EUR

Div. Rendite0,00%

WKNA14R82

ISINBE0974281132

SymbolBIOGF

BIOCARTIS GROUP NV 144A-Reg S Aktien News

Sortieren:Datum Meistgelesen

09.05.24GlobeNewswirePress release Biocartis Group NV: Biocartis Group NV provides an update regarding the publication of its annual report and the annual meeting

10.01.24GlobeNewswirePress release Biocartis Group NV: Disclosure of transparency notification (Article 14, first paragraph, of the Act of 2 May 2007 on the disclosure of large shareholdings)

10.01.24GlobeNewswirePress release Biocartis Group NV: Disclosure of transparency notification (Article 14, first paragraph, of the Act of 2 May 2007 on the disclosure of major shareholdings)

22.11.23GlobeNewswirePress release Biocartis Holdings Inc.: Recapitalization completed and product portfolio expansion

13.11.23GlobeNewswirePress release Biocartis NV: Biocartis Hosts Corporate Workshop and Announces Seven Idylla™ Abstracts to be Presented at AMP 2023 Annual Meeting

31.10.23GlobeNewswirePress release Biocartis Group NV: Announcement regarding Enforcement by Secured Creditors

20.10.23GlobeNewswirePress release Biocartis Group NV: Four Abstracts Showing Excellent Data for Idylla™ Presented at European Society of Molecular Oncology Congress (ESMO)

16.10.23GlobeNewswirePress release Biocartis Group NV: Biocartis Honors Breast Cancer Awareness Month with Launch of Breast Cancer Portfolio

12.10.23GlobeNewswirePress release Biocartis Group NV: Biocartis Announces Expansion of its Collaboration with APIS Assay Technologies to Commercialize the APIS ESR1 Mutations Kit

03.10.23GlobeNewswirePress Release Biocartis Group NV: Disclosure of transparency notification

26.09.23GlobeNewswirePress Release Biocartis Group NV: Biocartis announces H1 2023 Results and provides an update on the operational reorganization and recapitalization

26.09.23GlobeNewswirePress Release Biocartis Group NV: Agreement regarding recapitalization of operating subsidiaries by secured by secured creditors and wind down of listed holding company

21.09.23GlobeNewswirePress release Biocartis Group NV: Biocartis 2023 half-year results webcast on 26 September 2023

28.08.23GlobeNewswirePress Release Biocartis Group NV: Biocartis appoints new Medical Advisory Board (MAB) of renowned practice leaders

24.08.23GlobeNewswirePress Release Biocartis Group NV: Biocartis Announces 2023 Half-Year Results on 26 September 2023

10.08.23GlobeNewswirePress Release Biocartis Group NV: Biocartis Partners with Lilly to Explore Biomarker Testing for NSCLC Patients using the Idylla™ Platform

18.07.23GlobeNewswirePress release Biocartis Group NV: Biocartis appoints George Cardoza as new CFO and Head of Service Delivery

30.06.23GlobeNewswirePress release Biocartis Group NV: Disclosure of Outstanding Voting Securities

20.06.23GlobeNewswirePress release Biocartis Group NV: Disclosure of transparency notification

15.06.23GlobeNewswirePress release Biocartis Group NV: Biocartis announces planned operational reorganization and cost reduction program

08.06.23GlobeNewswirePress release Biocartis Group NV: Disclosure of transparency notification

05.06.23GlobeNewswirePress release Biocartis Group NV: Biocartis announces resignation CFO

12.05.23GlobeNewswirePress release Biocartis Group NV: Results of the Annual Shareholders’ Meeting held on 12 May 2023

09.05.23GlobeNewswirePress release Biocartis Group NV: Biocartis and HiloProbe to Collaborate on Colorectal Cancer Test

28.04.23GlobeNewswirePress release Biocartis Group NV: Disclosure of Outstanding Voting Securities

20.04.23GlobeNewswirePress release Biocartis Group NV: Biocartis Reports Results of First Quarter of 2023

11.04.23GlobeNewswirePress release Biocartis Group NV: Biocartis appoints Roger Moody as new CEO

11.04.23GlobeNewswirePress release Biocartis Group NV: Invitation to the Annual Shareholders’ Meeting

11.04.23GlobeNewswirePress release Biocartis Group NV: Biocartis Announces Publication of 2022 Annual Report

04.04.23GlobeNewswirePress release Biocartis Group NV: Biocartis and APIS Assay Technologies Sign Collaboration to Develop and Commercialise a Breast Cancer Subtyping Test on the Idylla™ platform

31.03.23GlobeNewswirePress release Biocartis Group NV: Disclosure of Outstanding Voting Securities

29.03.23GlobeNewswirePress release Biocartis Group NV: Biocartis To Publish 2022 Annual Report on 11 April 2023

03.03.23GlobeNewswirePress release Biocartis Group NV: Disclosure of transparency notification

02.03.23GlobeNewswirePress release Biocartis Group NV: Biocartis announces the US FDA 510(k) clearance for the Idylla™ MSI Test

28.02.23GlobeNewswirePress release Biocartis Group NV: Disclosure of Outstanding Voting Securities

24.02.23GlobeNewswirePress release Biocartis Group NV: Biocartis Creates New Share Option Plan and Cancels Outstanding Pool under Existing Share Option Plans

23.02.23GlobeNewswirePress release Biocartis Group NV: Biocartis announces 2022 results and 2023 outlook

22.02.23GlobeNewswirePress release Biocartis Group NV: Biocartis announces change in Board composition

16.02.23GlobeNewswirePress release Biocartis Group NV: Biocartis Announces 2022 Full Year Results on 23 February 2023

09.02.23GlobeNewswirePress release Biocartis Group NV: Biocartis Announces the Launch of the First Assay Developed With the New Idylla™ Flex Technology

BIOCARTIS GROUP NV 144A-Reg S News

BIOCARTIS GROUP NV 144A-Reg S News: auf dieser Seite finden Sie alle BIOCARTIS GROUP NV 144A-Reg S News und Nachrichten zur BIOCARTIS GROUP NV 144A-Reg S Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch BIOCARTIS GROUP NV 144A-Reg S News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um BIOCARTIS GROUP NV 144A-Reg S News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.